ICU Medical Stock Price and Value Analysis

ICU Medical (NasdaqGS:ICUI) in our automated value investing analysis, with the cash flow history and price comparison below.

Key Facts

Advertisement helps keep Trendshare free for most readers.

Hold-time calculator

Estimate how long you need to hold ICU Medical to reach your target.

Target type

ICUI Free Cash Flow Trend

Free Cash Flow trendline for ICUI
Free Cash Flow trendline for ICU Medical
CSV

Based on historical returns, we believe that ICU Medical can grow its free cash at a rate of about 8%. That's positive!

AdvantagesDisadvantagesNeutral
  • This company is solid.
  • This company is making money at a decent rate.
  • This stock looks overpriced.
  • This company has wild ups and downs.
  • This company pays no dividend.

Inside the ICUI Numbers

ICUI Price
(ICU Medical stock price per share)
$172.52
[?] ICUI Fair Price
(based on intrinsic value)
$133.43
[?] ICUI Safety Price (based on a variable margin of safety) $86.73
Try your own return

The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value.

Value per share:

[?] PE Ratio versus Sector 256% higher than other Healthcare stocks
[?] PE Ratio versus Industry 63% higher than other Medical Devices stocks
[?] Cash Yield 1.41%
[?] Free Cash Flow Jitter 107%

Insider Activity Summary

No open-market insider buys or sells are recorded for the last 12 months.

Recent Insider Activity

Open-market buys and sells reported by ICU Medical's officers, directors, and 10% owners on SEC Form 4. Routine transactions (tax withholding, option exercises, and stock grants) are excluded -- these are discretionary trades only.

Date Insider Type Shares Price
2025-05-19 FINNEY ELISHA W Sell 600 $138.92
2024-05-16 FINNEY ELISHA W Sell 300 $104.95
2024-02-29 SMITHS GROUP PLC Sell 830,000 $106.08
2024-02-29 Smiths Group International Holdings Ltd Sell 830,000 $106.08

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 1,672,002 shares shorted. With 24,559,667 shares available for purchase and an average trading volume over the past 10 trading days of 291,090, it would take at least 5.7 days for all of the short holders to cover their shorts.

Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth

Free Cash Flow by Fiscal Year

How to read this: free cash flow in plain terms, free cash flow jitter.

Each year names the SEC filer that reported it, so a change of filer shows up here.

Fiscal yearSEC filer (CIK)Free cash flow (USD millions)
2007 883984 17.9
2008 883984 12.8
2009 883984 33.9
2010 883984 14.4
2011 883984 46.4
2012 883984 49
2013 883984 47.1
2014 883984 47.7
2015 883984 47.6
2016 883984 71.8
2017 883984 125
2018 883984 116
2019 883984 41.7
2020 883984 147
2021 883984 183
2022 883984 -150
2023 883984 79.8
2024 883984 121
2025 883984 97.8

Download the yearly data as CSV.

Cash Conversion

How to read this: what free cash flow is, why earnings matter.

Over the 13 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $1,537 million against net income of $680 million, or 2.26 times. Net income was negative in 3 of the 16 years, and those years are left out of the ratio.

In 2025, operating cash flow was 245.69 times net income, compared with 1.41 times for the earliest three years (2010 to 2012).

In 2025, capital expenditures were $88 million, 49.0% of operating cash flow of $180 million, which leaves an estimated $91.8 million after capex. Across the 15 years with reported capex, it averaged 42.3% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.

Fiscal yearNet income (USD millions)Operating cash flow (USD millions)Capital expenditures (USD millions)Operating cash flow / net income
2010 29.9 33.1 23.2 1.11
2011 44.7 64.5 15.8 1.44
2012 41.3 66.3 19.2 1.61
2013 40.4 65.7 18.4 1.63
2014 26.3 66.3 16.6 2.52
2015 45 64.2 13 1.43
2016 63.1 89.9 23.4 1.43
2017 68.6 154 74.5 2.25
2018 28.8 160 92.7 5.56
2019 101 102 97.3 1.01
2020 86.9 223 92 2.56
2021 103 268 68.5 2.59
2022 -74.3 -62.1 90.3 n/a
2023 -29.7 166 83.9 n/a
2024 -118 204 79.4 n/a
2025 0.7 180 88 245.69

Where the Cash Went

How to read this: why companies buy back shares, dividend yield explained.

Over the 10 fiscal years from 2016 to 2025 with dividend or share repurchase facts, estimated free cash flow totaled $833 million. That estimate uses the average of up to five years of capital expenditures, not each year's own, so it is not a reported figure.

In 7 of the 10 years, cash spent repurchasing shares was at least 5% of that year's estimated free cash flow, and in those years it totaled $85.1 million. Smaller amounts are left out of this sentence because they can be shares withheld to pay employees' taxes on stock awards.

In 2025, cash spent repurchasing shares was $8.8 million, 9.0% of estimated free cash flow of $97.8 million.

Fiscal yearEstimated free cash flow (USD millions)Dividends paid (USD millions)Cash spent repurchasing shares (USD millions)Total returned (USD millions)Total as a percent of estimated free cash flow
2016 71.8 n/a 17.2 17.2 24.0%
2017 125 n/a 4.1 4.1 3.2%
2018 116 n/a 6.3 6.3 5.4%
2019 41.7 n/a 18.6 18.6 44.6%
2020 147 n/a 12.9 12.9 8.8%
2021 183 n/a 8.3 8.3 4.6%
2022 -150 n/a 10.9 10.9 n/a
2023 79.8 n/a 9.3 9.3 11.7%
2024 121 n/a 12 12 9.9%
2025 97.8 n/a 8.8 8.8 9.0%

Free cash flow here is an estimate: operating cash flow less the average of up to five years of capital expenditures. Cash spent repurchasing shares can include shares withheld to pay employees' taxes on stock awards. The entry n/a means the filings gave no usable figure, not that the amount was zero. Source: the company's annual reports to the SEC.

Revenue and Cash Margin

How to read this: earnings and margins.

Revenue was $188 million in 2007 and $2,231 million in 2025, a compound annual growth rate of 14.7% over 18 years. The starting revenue was under 10% of the latest, so that rate comes from a small base and says little about recent growth.

Revenue fell 6.3% from 2024 to 2025.

Our estimated free cash flow was $97.8 million in 2025, 4.4% of revenue. In 2007 the estimated margin was 9.5%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.

Fiscal yearRevenue (USD millions)Estimated free cash flow (USD millions)Estimated free cash flow / revenue
2007 188 17.9 9.5%
2008 205 12.8 6.3%
2009 229 33.9 14.8%
2010 283 14.4 5.1%
2011 302 46.4 15.3%
2012 317 49 15.5%
2013 314 47.1 15.0%
2014 309 47.7 15.4%
2015 342 47.6 13.9%
2016 379 71.8 18.9%
2017 1,293 125 9.7%
2018 1,400 116 8.3%
2019 1,266 41.7 3.3%
2020 1,271 147 11.5%
2021 1,316 183 13.9%
2022 2,280 -150 -6.6%
2023 2,259 79.8 3.5%
2024 2,382 121 5.1%
2025 2,231 97.8 4.4%

Balance Sheet

How to read this: how debt and assets are compared, the current ratio.

In 2025, cash and equivalents were $308 million against total liabilities of $1,927 million, or 16.0% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.

Total liabilities were 47.6% of total assets in 2025, compared with 10.7% in 2008, an increase of 36.8 percentage points.

Stockholders equity was $2,124 million in 2025, compared with $253 million in 2008, a rise of 739.4%.

Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 3.0% in 2025. Invested capital here is total assets less cash and current liabilities.

Fiscal yearTotal assets (USD millions)Cash and equivalents (USD millions)Total liabilities (USD millions)Stockholders equity (USD millions)
2008 283 55.7 30.4 253
2009 309 51.2 44.1 263
2010 310 78.8 37.9 272
2011 361 99.6 40.5 321
2012 429 147 37.7 391
2013 500 226 34.9 465
2014 541 276 32.9 508
2015 627 336 47 580
2016 705 445 44.5 660
2017 1,497 290 299 1,198
2018 1,585 345 322 1,264
2019 1,692 269 315 1,377
2020 1,764 396 261 1,502
2021 1,881 553 265 1,616
2022 4,516 209 2,426 2,090
2023 4,378 254 2,255 2,123
2024 4,204 309 2,239 1,965
2025 4,051 308 1,927 2,124

What the Price Implies

How to read this: discounted cash flow, intrinsic value.

At today's price of $172.52, our model's value equals that price if free cash flow grows an average of 15.8 percent a year over the 10 projection years. Our model assumes 7.8 percent a year for this stock, so the price implies growth of 15.8 percent, which is above the 7.8 percent our model assumes. This is the growth the price implies under our model, not a forecast of growth or a price target.

The table shows the same calculation at a price 20 percent lower and 20 percent higher than today's price, and the model's own growth rate at its fair price.

The model starts from the company's average free cash flow of $60.8 million, grows it over 10 years along the year-by-year growth path stored for this stock (the pace fades over the years, and the implied rate keeps that shape, so the rates here are 10-year averages), discounts it at 10.1 percent a year, adds a terminal value that grows 2.5 percent a year after year 10, adds the company's net worth, and divides by shares outstanding.

The baseline is the company's average free cash flow, and cyclical companies can mislead it.

CasePrice per shareAverage annual free cash flow growth
20 percent below the current price $138.02 9.0%
Current price $172.52 15.8%
20 percent above the current price $207.02 20.3%
Our model (stored fair price) $133.43 7.8%

Model assumptions: 10.1 percent discount rate, 2.5 percent terminal growth, 10 projection years. To try your own growth rate, use the intrinsic value calculator on this page. It uses a simpler single-rate model, so its results will not match the figures above exactly.

Price Versus Our Estimated Value

ICU Medical is priced at $172.52, above our fair value estimate of $133.43 and its safe value of $86.73.

ICU Medical reported positive free cash flow in 18 of the 19 fiscal years we have from its current SEC filer.

Average free cash flow over the last three years of data was $99.6 million, and across the first three years it was $21.5 million; over the period it rose sharply.

Free cash flow is volatile from year to year, with a variability measure of 107%.

Before you act on any of this, read what a margin of safety means and check the company's own filings.

No dividend yield is recorded for ICU Medical in our data.

Compared With Its Sector and Industry

How to read this: the price to earnings ratio.

Its trailing P/E ratio is 256% above the average for stocks in the Healthcare sector.

Its trailing P/E ratio is 63% above the average for stocks in the Medical Devices industry.

A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.

Closest Industry Peers

These are companies in the Medical Devices industry, the ones closest in market capitalization to ICU Medical, limited to companies whose pages we publish. The figures come from our latest data for each company.

CompanyMarket cap (USD millions)P/EDividend yieldCash yieldPrice versus our estimate
ICU Medical (ICUI) 4,315 72.2 - 1.4% 29% above
Integer Holdings Corporation (ITGR) 4,317 42.6 - - 147% above
LivaNova PLC (LIVN) 4,998 26.0 - - 317% above
Merit Medical Systems (MMSI) 5,053 31.6 - 1.1% 117% above
Haemonetics Corporation (HAE) 5,472 53.2 - 1.7% 132% above
UFP Technologies (UFPT) 2,253 29.7 - 0.1% 395% above
Teleflex Incorporated (TFX) 6,408 79.6 0.8% 5.7% 24% below

Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.

Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.

SEC Filer History

Every fiscal year on this page is reported by one SEC filer, CIK 883984.

Each figure on this page comes from that filer.

Risks to This Analysis

How to read this: understanding investment risk.

  • Free cash flow was negative in 1 of the 19 years we have.
  • Free cash flow is volatile from year to year, so the estimates depend heavily on which years are included.
  • These figures are automated calculations from SEC filings and the recent price. They may contain errors, and they do not reflect lawsuits, management changes, or other events the filings do not show.

How This Page Is Made

Latest annual report used
Fiscal year 2025
Price and market data last refreshed
2026-11-20
Model assumptions last reviewed
2026-11-09

Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.

Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.

The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.

This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.

Read the filings yourself: ICUI annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.

Advertisement supports free stock analysis content.

Questions to Answer Before You Invest in ICUI

Does ICU Medical have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.

Worked example: ICUI

This example shows how we apply the Trendshare checklist to ICUI: earnings power, cash generation, valuation, and margin of safety.

We check: business quality, free cash flow, P/E, and margin of safety.

  1. Step 1 — Snapshot

    • Price: 172.52
    • Market cap: $4.3B
    • EPS: 2.39
  2. Step 2 — Valuation checks

    • P/E: 72.184
    • FCF yield: 1.4%
    • Date checked: Nov 20, 2026
  3. Step 3 — Margin of safety

    • Compare price to fair value and safety price.
    • Look for durable cash generation and reasonable leverage.
    • Decide if it passes your personal checklist.